glucosamine hydrochloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: glucosamine hydrochloride
• 英文别名: (3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)azanium;chloride
• 化学式: C₆H₁₃NO₅*ClH
• 分子量: 215.634
• InChiKey: CBOJBBMQJBVCMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.99
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  124
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  马来酸酐 、 glucosamine hydrochloride 在 溶剂黄146 作用下， 反应 3.0h， 以77%的产率得到N-glucose hydrochloride maleamic acid
  参考文献：
  名称：

  Maleamic acid monomer and preparation method and use thereof

  摘要：

  一种马来酰氨单体，以及其制备方法和用途。该单体的结构式如下：式（1），其中，R选自所述发明提供的马来酰氨单体可用作共聚单体，制备耐高温和耐钙盐的聚合物。

  公开号：

  US10538484B1

文献信息

• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。
• [EN] ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS<br/>[FR] COMPOSÉS SE LIANT À L'ASGPR POUR LA DÉGRADATION DE PROTÉINES EXTRACELLULAIRES
  申请人：AVILAR THERAPEUTICS INC

  公开号：WO2021155317A1

  公开（公告）日：2021-08-05

  Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

  描述了将一个与外细胞蛋白结合配体结合的阿斯利康糖蛋白受体（ASGPR）结合配体的化合物和组合物，用于选择性降解体内靶外细胞蛋白以治疗由外细胞蛋白介导的疾病。
• Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents
  申请人：Aime Silvio

  公开号：US20070258905A1

  公开（公告）日：2007-11-08

  The present invention relates to a new class of paramagnetic ion-based contrast agents of molecular weight lower than 3.5 kDa that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents and that are further characterized by a higher relaxivity.

  本发明涉及一种新的顺磁离子基对比剂，其分子量低于3.5 kDa，显示类似于常用的T1通用非血管内对比剂的药代动力学特征，并且具有更高的弛豫度。
• Contrast agents endowed with high relaxivity
  申请人：Aime Silvio

  公开号：US20110256067A1

  公开（公告）日：2011-10-20

  The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.

  本发明涉及一种新型的基于顺磁离子的对比剂类别，其化学式为(I)，其中螯合骨架部分通过一个或多个多羟基链的存在高度功能化，表现出与常用的T1通用非血管外用对比剂(NSA)相似的药代动力学特征，但具有更高的弛豫度。
• Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10690651B2

  公开（公告）日：2020-06-23

  The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.

  本文公开的发明一般涉及诊断、评估疾病风险、治疗和预防细菌性阴道病（BV）及相关疾病的方法和试剂盒。其他实施方案包括开发与疾病风险增加相关的代谢图谱的方法，以及开发基于干扰代谢网络治疗 BV 的新方法。

表征谱图